HCWB HCW Biologics Inc.
$1.14▲ +3.64%
Healthcare
Other
Volume 19.9K
Avg Volume (10D) 271.6K
Key Metrics & Fundamentals
Market Cap
$2.55M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.09 - 23.94
% vs 50 MA
-42.53%
% vs 200 MA
-72.89%
RSI-14
30.0
MACD Histogram
+0.0200
Beta (1Y vs SPY)
0.95
Free Cash Flow
-$3.97M
Gross Rev
$135,568
Gross Profit
-$93,887
EBITDA
-$2.53M
COGS
$229,455
Operating Exp
$3.06M
Operating Income
-$3.15M
EBIT
-$3.15M
Pretax Income
-$5.22M
Net Income
-$5.22M
EPS (Diluted)
-11.58
Price & Volume History
Loading chart…
Recent News
HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
GlobeNewswire · Oct 9, 2026 9:00 AM ET
HCW Biologics Announces Pricing of $1.5 Million Private Placement
GlobeNewswire · Sep 24, 2026 8:25 AM ET
HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent
InvestorsHub · Sep 8, 2026 9:49 AM ET
HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells
GlobeNewswire · Sep 8, 2026 8:50 AM ET
HCW Biologics Receives US Patent Allowance for HCW9302 in Alopecia Areata
MT Newswires · Sep 2, 2026 9:29 AM ET
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
GlobeNewswire · Sep 2, 2026 9:00 AM ET
HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells
GlobeNewswire · Aug 25, 2026 9:00 AM ET
HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results
GlobeNewswire · Aug 14, 2026 3:15 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See HCWB's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.